ARS Pharmaceuticals (SPRY) Income towards Parent Company (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Income towards Parent Company data on file, last reported at -$95.9 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 156.94% year-over-year to -$95.9 million; the trailing twelve-month figure through Mar 2026 stood at -$474.8 million (down 123.05% YoY), and the FY2025 full-year result was -$171.3 million, down 2241.76% from the prior year.
• Income towards Parent Company declined to -$95.9 million in Q1 2026, from -$43.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $47.3 million in Q4 2024 to a low of -$39.4 billion in Q1 2023.
• A 5-year average of -$5.5 billion and a median of -$67.4 million in 2024 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company slumped 339646.93% in 2023 and surged 571.87% in 2024, its largest moves.
• Tracing SPRY's Income towards Parent Company over 5 years: stood at -$15.1 million in 2022, then jumped by 33.83% to -$10.0 million in 2023, then surged by 571.87% to $47.3 million in 2024, then sank by 192.39% to -$43.7 million in 2025, then tumbled by 119.7% to -$95.9 million in 2026.
• Business Quant data shows SPRY's Income towards Parent Company at -$95.9 million in Q1 2026, -$43.7 million in Q4 2025, and -$113.0 million in Q3 2025.